Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Dal Pan

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Pain|October 6, 2020
Patterns of opioid analgesic use in the U.S., 2009 to 2018Corinne Woods, Grace Chai, Tamra Meyer, et al.
Pharmacoepidemiology and Drug Safety|December 22, 2016
Drug availability adjustments in population-based studies of prescription opioid abuseAlex Secora, James Phillip Trinidad, Rongmei Zhang, et al.
Pharmacoepidemiology and Drug Safety|March 27, 2015
Patient understanding of drug risks: an evaluation of medication guide assessmentsCaitlin Knox, Christian Hampp, Mary Willy, et al.
Drug Safety|March 26, 2017
Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety WithdrawalsAndreas Schick, Kathleen L Miller, Michael Lanthier, et al.
Drug Safety|February 3, 2022
Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug AdministrationDavid Croteau, Ellen Pinnow, Eileen Wu, et al.
Journal of the American Academy of Dermatology|April 26, 2011
Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patientsNamita Kothary, Ida-Lina Diak, Allen Brinker, et al.
Pharmacoepidemiology and Drug Safety|August 14, 2020
FDA postmarketing safety labeling changes: What have we learned since 2010 about impacts on prescribing rates, drug utilization, and treatment outcomesMatthew Rosenberg, Sarah Sheehan, Esther Zhou, et al.
JAMA Psychiatry|January 10, 2024
Trends in Incident Prescriptions for Behavioral Health Medications in the US, 2018-2022Grace Chai, Jing Xu, Sonal Goyal, et al.
Pharmacoepidemiology and Drug Safety|January 3, 2013
Evaluation of FDA safety-related drug label changes in 2010Jean Lester, George A Neyarapally, Earlene Lipowski, et al.
Clinical Pharmacology and Therapeutics|May 31, 2021
The Impact of Variability in Patient Exposure During Premarket Clinical Development on Postmarket Safety OutcomesSanae Cherkaoui, Ellen Pinnow, Ilynn Bulatao, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Pain|October 6, 2020
Patterns of opioid analgesic use in the U.S., 2009 to 2018Corinne Woods, Grace Chai, Tamra Meyer, et al.
Pharmacoepidemiology and Drug Safety|December 22, 2016
Drug availability adjustments in population-based studies of prescription opioid abuseAlex Secora, James Phillip Trinidad, Rongmei Zhang, et al.
Pharmacoepidemiology and Drug Safety|March 27, 2015
Patient understanding of drug risks: an evaluation of medication guide assessmentsCaitlin Knox, Christian Hampp, Mary Willy, et al.
Drug Safety|March 26, 2017
Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety WithdrawalsAndreas Schick, Kathleen L Miller, Michael Lanthier, et al.
Drug Safety|February 3, 2022
Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug AdministrationDavid Croteau, Ellen Pinnow, Eileen Wu, et al.
Journal of the American Academy of Dermatology|April 26, 2011
Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patientsNamita Kothary, Ida-Lina Diak, Allen Brinker, et al.
Pharmacoepidemiology and Drug Safety|August 14, 2020
FDA postmarketing safety labeling changes: What have we learned since 2010 about impacts on prescribing rates, drug utilization, and treatment outcomesMatthew Rosenberg, Sarah Sheehan, Esther Zhou, et al.
JAMA Psychiatry|January 10, 2024
Trends in Incident Prescriptions for Behavioral Health Medications in the US, 2018-2022Grace Chai, Jing Xu, Sonal Goyal, et al.
Pharmacoepidemiology and Drug Safety|January 3, 2013
Evaluation of FDA safety-related drug label changes in 2010Jean Lester, George A Neyarapally, Earlene Lipowski, et al.
Clinical Pharmacology and Therapeutics|May 31, 2021
The Impact of Variability in Patient Exposure During Premarket Clinical Development on Postmarket Safety OutcomesSanae Cherkaoui, Ellen Pinnow, Ilynn Bulatao, et al.
Pageof 4